Literature DB >> 17390023

Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma.

Susanne Heinsohn1, Ulrike Evermann, Udo Zur Stadt, Stefan Bielack, Hartmut Kabisch.   

Abstract

The retinoblastoma (RB) tumour suppressor gene is implicated in the development of several malignancies including osteosarcoma. Recent studies postulated its loss of heterozygosity (LOH) to be a poor prognostic factor at diagnosis of osteosarcoma (OS). It remains unclear whether LOH of the RB gene is suitable as a prognostic factor at diagnosis in patients with osteosarcoma. In this study we aimed to determine the early prognostic value of RB-LOH as well as the ability of denaturating high performance liquid chromatography (DHPLC) to detect LOH at this gene locus in comparison to classical PAGE. We therefore analysed 41 samples of OS on restriction fragment length polymorphisms in introns 1, 17 and 25, and variable numbers of tandem repeats (VNTRs) in intron 20. PCR fragments were separated on 1.5% agarose gel electrophoresis. VNTRs with length differentiation of only a few base pairs were analysed by 8% PAA/Spreadex gels and additionally by DHPLC. One-hundred percent concordance was observed between the results obtained by classical PAGE and DHPLC. The latter improved intron 20 analysis as a sensitive and high throughput method for detecting LOH. Overall we found 16 RB-LOH in 41 OS (39%). Three tumours exhibited additional microsatellite instability. There was no significant correlation of the event-free- and overall-survival rate or response to chemotherapy with RB-LOH found in our study. LOH positivity was associated with a significantly younger age at diagnosis. In conclusion RB-LOH could not be verified as a poor prognostic factor for osteosarcoma in the present study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390023

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma.

Authors:  Ioannis Panagiotidis; Dimitrios Christoulas; Evangelos Terpos
Journal:  Ann Transl Med       Date:  2016-12

2.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

3.  Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma.

Authors:  Milcah C Scott; Aaron L Sarver; Hirotaka Tomiyasu; Ingrid Cornax; Jamie Van Etten; Jyotika Varshney; M Gerard O'Sullivan; Subbaya Subramanian; Jaime F Modiano
Journal:  J Biol Chem       Date:  2015-09-16       Impact factor: 5.157

4.  CDC20 and its downstream genes: potential prognosis factors of osteosarcoma.

Authors:  Man-Si Wu; Qing-Yu Ma; Dong-Dong Liu; Xiao-Juan Li; Li-Juan Deng; Nan Li; Jingnan Shen; Zhiqiang Zhao; Jia-Xu Chen
Journal:  Int J Clin Oncol       Date:  2019-07-05       Impact factor: 3.402

Review 5.  [Molecular characterization of osteosarcomas].

Authors:  D Baumhoer
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 6.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

7.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

8.  The genetics of osteosarcoma.

Authors:  Jeff W Martin; Jeremy A Squire; Maria Zielenska
Journal:  Sarcoma       Date:  2012-05-20

Review 9.  Molecular Markers of Pediatric Solid Tumors-Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions.

Authors:  Joanna Trubicka; Wiesława Grajkowska; Bożenna Dembowska-Bagińska
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

10.  Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma.

Authors:  Jingmin Shu; Lihua Li; Anne E Sarver; Emily A Pope; Jyotika Varshney; Venugopal Thayanithy; Logan Spector; David A Largaespada; Clifford J Steer; Subbaya Subramanian
Journal:  Oncotarget       Date:  2016-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.